Satraplatin's Stumble: Is Accelerated Approval Under Threat?
Executive Summary
It was a shocking summer for Germany's GPC Biotech, whose stock lost over 70% of its value in late July after an FDA advisory committee recommended that FDA delay considering prostate cancer candidate satraplatin for approval. Regulatory snafus are nothing new, but this story sends some clear messages to the industry.
You may also be interested in...
Phase III Prostate Cancer Failures: Taxotere to Blame?
Had a Phase III failure? Don't believe the data. Trial design, concurrent therapies, patient selection, or even the conventional diagnostic indicator for the disease could be at fault, as illustrated by a handful of late-stage trip-ups during 2007.
Phase III Prostate Cancer Failures: Taxotere to Blame?
Had a Phase III failure? Don't believe the data. Trial design, concurrent therapies, patient selection, or even the conventional diagnostic indicator for the disease could be at fault, as illustrated by a handful of late-stage trip-ups during 2007.
Europe's New Spec Pharma Models
Spec pharma has created significant value in the US, but not, so far, in Europe. Still, Europe's spec pharma hopefuls aren't giving up, and they're trying out variations on the theme--some starting with infrastructure, others with products.